Sterling Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Sterling Capital Management's ACAD Position: Q3 2026 in Review
Sterling Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 708% in Q3 2026, buying an estimated $102K and bringing the position to 4,337 shares worth $87.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1496.
Sterling Capital Management first reported a position in ACAD in Q3 2024 and has held it in 9 quarters since. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Sterling Capital Management held 4,337 shares of Acadia Pharmaceuticals worth $87.4K as of Q3 2026.
- Sterling Capital Management bought 3,800 Acadia Pharmaceuticals shares in Q3 2026, an estimated $102K.
- Acadia Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1496 holding.
- Sterling Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.